SCHEMBL3570562

SCHEMBL3570562

CN(C)Cc1ccccc1-c1ccc(NC(=O)C(NC(=O)Nc2ccc(Cl)cc2)c2ccccc2F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 5/20 0.44
F10 P00742 3/20 0.43
CNR1 P21554 2/20 0.43
ITGB1 P05556 1/20 0.41
ITGA4 P13612 1/20 0.41
ITGB7 P26010 1/20 0.41
LSS P48449 1/20 0.39
F2 P00734 1/20 0.39
KLK1 P06870 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 1/20 0.38
CNR2 P34972 1/20 0.37
P2RY1 P47900 1/20 0.37
KCNH2 Q12809 1/20 0.37
MEN1 O00255 2/20 0.37
ALDH1A1 P00352 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
FPR1 P21462 1/20 0.37
FPR2 P25090 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569909 0.91 F10 (0.48) UTS2RF10CNR1ITGB1ITGA4
SCHEMBL3559107 0.90 F10 (0.46) UTS2RF10CNR1ITGB1ITGA4
SCHEMBL3567714 0.83 P2RY1 (0.46) F10F2KLK1NPC1RAB9A
SCHEMBL3570559 0.80 F10 (0.41) UTS2RF10CNR1ITGB1ITGA4
SCHEMBL3557262 0.78 CNR1 (0.50) CNR1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL8264048 0.78 F10 (0.44) UTS2RF10CNR1NPC1RAB9A
SCHEMBL3570295 0.77 UTS2R (0.42) UTS2RCNR1CNR2MEN1KMT2A
SCHEMBL3564018 0.75 F10 (0.43) UTS2RF10CNR1EP300
SCHEMBL3559165 0.74 CNR1 (0.38) UTS2RCNR1KLK1CNR2MEN1
SCHEMBL3569304 0.74 CNR1 (0.52) CNR1NPC1RAB9ACNR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 UTS2R 52/4885F10 9/4885CNR1 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.